<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main"></title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Allergy</roleName><forename type="first">William</forename><forename type="middle">E</forename><surname>Berger</surname></persName>
							<email>weberger@uci.edu</email>
							<affiliation key="aff0">
								<orgName type="department">ciates of Southern California</orgName>
								<address>
									<postCode>92691</postCode>
									<settlement>Mission Viejo</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Asthma</forename><surname>Asso</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">ciates of Southern California</orgName>
								<address>
									<postCode>92691</postCode>
									<settlement>Mission Viejo</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wytske</forename><surname>Fokkens</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">ciates of Southern California</orgName>
								<address>
									<postCode>92691</postCode>
									<settlement>Mission Viejo</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">5AFC3CF78E80AFE7605E1FD0535CECDB</idno>
					<idno type="DOI">10.1111/all.12903</idno>
					<note type="submission">Accepted for publication 1 April 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:43+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>children</term>
					<term>Dymista</term>
					<term>fluticasone propionate</term>
					<term>MP29-02</term>
				</keywords>
			</textClass>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The objective was to evaluate the efficacy of MP-AzeFlu (Dymista Ò ) vs fluticasone propionate (FP), (both 1 spray/nostril bid), in children with allergic rhinitis (AR).</s><s>MP-AzeFlu combines azelastine hydrochloride, FP and a novel formulation in a single spray.</s><s>Children were randomized in a 3 : 1 ratio to MP-AzeFlu or FP in this open-label, 3-month study.</s><s>Efficacy was assessed in children aged ≥ 6 to &lt;12 years (MP-AzeFlu: n = 264; FP: n = 89), using a 4-point symptom severity rating scale from 0 to 3 (0 = no symptoms; 3 = severe symptoms).</s><s>Over the 3-month period, MP-AzeFlu-treated children experienced significantly greater symptom relief than FP-treated children (Diff: À0.14; 95% CI: À0.28, À0.01; P = 0.04), noted from the first day (particularly the first 7 days) and sustained for 90 days.</s><s>More MP-AzeFlu children achieved symptom-free or mild symptom severity status, and did so up to 16 days faster than FP.</s><s>MP-AzeFlu provides significantly greater, more rapid and clinically relevant symptom relief than FP in children with AR.</s></p><p><s>Intranasal corticosteroids (INS) are recommended for the treatment of children with allergic rhinitis (AR) <ref type="bibr" target="#b0">(1)</ref>.</s><s>However, they provide insufficient symptom control for many.</s><s>Considering that AR is associated with poor asthma control <ref type="bibr" target="#b1">(2)</ref>, is a predictor of wheezing onset in school-aged children (3) and poorer examination performance at school (4), it is important to get it under control.</s><s>Unfortunately, AR is undiagnosed and undertreated in children <ref type="bibr" target="#b4">(5)</ref>.</s></p><p><s>MP-AzeFlu (Dymista Ò , Meda, Solna, Sweden) comprises an intranasal antihistamine [azelastine hydrochloride (AZE)], an INS [fluticasone propionate (FP)] and a novel formulation in a single spray.</s><s>Its efficacy and safety in adults and adolescent AR patients are well established <ref type="bibr" target="#b5">(6)</ref><ref type="bibr" target="#b6">(7)</ref><ref type="bibr" target="#b7">(8)</ref><ref type="bibr" target="#b8">(9)</ref><ref type="bibr" target="#b9">(10)</ref>, providing twice the overall nasal and ocular symptom relief as an INS or intranasal H1-antihistamine, and more complete and rapid symptom control <ref type="bibr" target="#b5">(6)</ref>.</s></p><p><s>A lower treatment effect has been observed in paediatric allergy trials <ref type="bibr" target="#b10">(11)</ref><ref type="bibr" target="#b11">(12)</ref><ref type="bibr" target="#b12">(13)</ref>, possibly confounded by caregiver assessment <ref type="bibr" target="#b13">(14,</ref><ref type="bibr" target="#b14">15)</ref>.</s><s>The present study was primarily designed to assess the long-term safety of MP-AzeFlu (the results of which will be published in full elsewhere).</s><s>Efficacy was assessed secondarily using a simple scoring system in an effort to minimize this confounder.</s><s>The objective was to evaluate the efficacy of MP-Aze-Flu compared to FP in children aged ≥ 6 to &lt;12 years, with AR.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol</head><p><s>This was a prospective, randomized, active-controlled, parallel-group, 3-month, open-label safety trial in children with AR carried out at 42 investigational sites in the USA (March-October 2013).</s><s>Ethics approval was obtained (Chesapeake Research Review Inc., Columbia, MD, USA), and the study conducted in accordance with Good Clinical Practice.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Participants</head><p><s>Male and female children aged ≥ 4 to &lt;12 years (at screening visit), with a history of AR and who may benefit from treatment with MP-AzeFlu, in the opinion of the investigator (based on medical history and physical examination), were included.</s><s>These children were free of any disease or concomitant treatment that could have interfered with the interpretation of the study.</s><s>Those with superficial or moderate nasal erosion, nasal mucosal ulceration or nasal septum perforation, who had nasal surgery within the last year, had significant pulmonary disease (excluding intermittent asthma), a hypersensitivity to AZE and/or FP or had used any investigation drug within 30 days prior to providing informed consent were excluded.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Planned interventions and timing</head><p><s>The study comprised a 2-to 30-day lead-in period, and a 3month treatment period, with study visits on Days, 1, 15, 30, 60 and 90.</s><s>On Day 1, eligible children were randomized in a 3 : 1 ratio to either MP-AzeFlu nasal spray (daily dose: AZE 548 lg, FP 200 lg) or FP nasal spray (Roxane; daily dose 200 lg), both administered as 1 spray/nostril bid.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy variables</head><p><s>Each child (or caregiver) completed a 24-h reflective total symptom score (TSS) evaluation, scored daily in the morning during the lead-in period and prior to the AM dose in the treatment period, in response to the question 'how were your allergy symptoms over the past 24 h?'.</s></p><p><s>Allergy symptoms were scored from 0 (none/absent: no symptoms present), 1 (mild: symptoms clearly present, but minimal awareness and easily tolerated), 2 (moderate: definite awareness of symptoms that were bothersome but tolerable) to 3 (severe: hard to tolerate and caused interference with activities of daily living and/or sleeping).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety variables</head><p><s>Adverse events, nasal examination findings and vital signs were assessed.</s><s>These data will be published in full separately <ref type="bibr" target="#b15">(16)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p><s>Because it was a safety study, no inferential efficacy analysis were predefined in the protocol.</s><s>The development focus of the paediatric programme was in the age range of 6-to 11-year-olds with some exploration in 4-to 5-year-olds.</s><s>The mean change in TSS from baseline to each clinic visit was analysed post hoc for all randomised children aged ≥ 6 to &lt;12 years old who took the drug.</s><s>These data were analysed with a mixed-model ANCOVA (baseline as covariate; age class, visit and treatment as fixed effects).</s><s>Missing data were not replaced.</s><s>Time to response was analysed by Kaplan-Meier estimates and log-rank tests.</s><s>Response was defined as change in TSS from a baseline of 2 or 3 (i.e.</s><s>moderate to severe) to a maximum of 1 (i.e.</s><s>mild at most).</s><s>For symptomatic children (i.e.</s><s>baseline value ≥ 2), this is equivalent to a 50% reduction from baseline in AM + PM reflective total nasal symptom score (rTNSS) assessed in other studies <ref type="bibr" target="#b5">(6,</ref><ref type="bibr" target="#b6">7)</ref>.</s><s>Mean % of days with none to mild symptoms (i.e.</s><s>TSS 0 or 1) was also calculated for both groups.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Child disposition</head><p><s>A total of 405 children were randomized to MP-AzeFlu or FP treatment.</s><s>A total of 51 children (aged ≤ 5 years) were excluded from the efficacy analysis, as per the statistical plan efficacy was assessed in those aged ≥ 6 to &lt;12 years.</s><s>One child was excluded from the FP group (did not receive medication), yielding n = 264 and n = 89 in the MP-AzeFlu and FP treatment groups, respectively.</s><s>Time-to-response analysis was performed for symptomatic children (i.e.</s><s>TSS above 2 at baseline; MP-AzeFlu: n = 124; FP: n = 44).</s><s>Of these, 15 children (6%) did not complete the study in the MP-AzeFlu group (n = 4 AE, n = 1 treatment failure, n = 1 protocol violation, n = 2 noncompliance, n = 3 withdrawal, n = 2 lost to follow-up and n = 2 other) and eight children (9%) failed to complete from the FP group (n = 3 AE, n = 1 protocol violation, n = 1 withdrawal, n = 2 lost to follow-up, n = 1 other).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Child baseline and demographic information</head><p><s>Similar baseline characteristics were observed in the MP-Aze-Flu and FP groups (Table <ref type="table" target="#tab_0">1</ref>).</s><s>The proportion of children with concomitant asthma was 4.86% and 4.90% in the MP-AzeFlu and FP groups, respectively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reflective total symptom score</head><p><s>Children treated with MP-AzeFlu experienced a À0.68 pt reduction in TSS, significantly greater than that afforded by FP (À0.54 pt reduction; Diff: À0.14; 95% CI: À0.28,À0.01;</s><s>P = 0.0410).</s><s>The superiority of MP-AzeFlu was noted from the first day of assessment, particularly during the first 7 days of treatment, and sustained for 90 days.</s><s>More children treated with MP-AzeFlu (eight of 10 children) achieved symptom-free or at most mild symptom severity in the first month of treatment, and did so up to 16 days faster than FP (Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>More children treated with MP-AzeFlu experienced none or mild symptoms during the 3-month study period [73.4% (SD 28.8)] than those treated with FP [66.0%</s><s>(SD 34.2)].</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>MP-AzeFlu provided significantly better AR symptom relief than FP in children aged ≥ 6 to &lt;12 years, the first time the efficacy of INS has been exceeded in this population.</s><s>Effect size was similar to that seen in adult and adolescent SAR patients <ref type="bibr" target="#b5">(6)</ref>.</s><s>In the current study, MP-AzeFlu induced a À0.68 point TSS reduction from baseline, a À0.14 point difference vs FP, corresponding to a À5.44 point reduction and À1.12 point difference, respectively, on the 24-point rTNSS scale used in the adult/adolescent SAR trials (6, 7).</s><s>Furthermore, approximately eight of 10 children treated with MP-AzeFlu in the current study achieved symptomfree or at most mild symptom severity in the first month of treatment, and did so up to 16 days faster than FP; comparable to the proportion of adult and adolescent patients with perennial AR over the same time period <ref type="bibr" target="#b7">(8)</ref>, which should positively influence concordance with MP-AzeFlu therapy.</s><s>Approximately three quarters of children treated with MP-AzeFlu experienced no or only mild symptoms during the 3-month treatment period.</s><s>Achieving AR symptom control (and rapidly) is particularly important in children due to the negative impact of uncontrolled disease on school performance (4) and on asthma control <ref type="bibr" target="#b1">(2)</ref>.</s></p><p><s>Previously, MP-AzeFlu has demonstrated statistical superiority over placebo in children (aged ≥ 6 to &lt;12 years) with moderate/severe SAR <ref type="bibr" target="#b16">(17,</ref><ref type="bibr" target="#b17">18)</ref>, and as the extent of child self-rating increased, so too did the treatment difference between MP-AzeFlu and placebo.</s><s>However, efficacy was assessed using an endpoint designed for adolescent/ adult populations (i.e. by rTNSS), in line with regulatory requirement, and could be rated by either children or caregivers.</s><s>The present study was designed to minimize assessment effort and bias using a much simplified and childfriendly efficacy assessment tool.</s><s>Using this simple 4-point  rating scale significant superiority of MP-AzeFlu was detected vs an active treatment.</s></p><p><s>Limitations of the current study include the open-label design and that it was primarily a safety study, with no assessment of quality of life or inferential efficacy analysis predefined in the protocol.</s><s>However, the applied statistical method used to assess efficacy is straightforward and standard.</s><s>In addition, the low number of clinic visits and the simple method of efficacy assessment make this trial quite pragmatic in nature and representative of response achievable in real life.</s><s>Use of the simple 4-point severity scoring system was sensitive enough to detect difference in efficacy between two active treatments.</s><s>MACVIA ARIA recommends another simple tool, the visual analogue scale, to assess disease control and guide treatment decisions <ref type="bibr" target="#b18">(19)</ref>.</s><s>These tools should be strongly considered for inclusion in AR trials in children.</s></p><p><s>In conclusion, MP-AzeFlu provides significantly greater, more complete and more rapid AR symptom control than FP in children (aged ≥ 6-12 years) and has been granted approval for use in this age group by the FDA.</s><s>Efficacy assessment in AR trials in children might be improved by use of simple tools.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 Time to achieve at most mild allergic rhinitis symptom severity in children with moderate-to-severe symptoms at baseline during the first month of treatment with either MP-AzeFlu (n = 124) or fluticasone propionate (FP: n = 44), both 1 spray/nostril bid, in children aged ≥6 to 12 years.</s><s>Time to response was analysed by Kaplan-Meier estimates and log-rank tests.</s></p></div></figDesc><graphic coords="3,116.22,519.54,347.87,152.27" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Demographic and baseline characteristics in children aged ≥ 6 to &lt;12 years</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell cols="2">Symptomatic patients (baseline</cell></row><row><cell></cell><cell>All patients</cell><cell></cell><cell>TSS ≥ 2)</cell><cell></cell></row><row><cell></cell><cell>MP-AzeFlu</cell><cell>FP</cell><cell>MP-AzeFlu</cell><cell>FP</cell></row><row><cell>Characteristic</cell><cell>(n = 264)</cell><cell>(n = 89)</cell><cell>(n = 124)</cell><cell>(n = 44)</cell></row><row><cell>Age, n (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>≥6 to &lt;9 years</cell><cell>128 (48.5)</cell><cell>44 (49.4)</cell><cell>63 (50.8)</cell><cell>21 (47.7)</cell></row><row><cell>≥9 to &lt;12 years</cell><cell>136 (51.5)</cell><cell>45 (50.6)</cell><cell>61 (49.2)</cell><cell>23 (52.3)</cell></row><row><cell>Gender, n (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Male</cell><cell>158 (59.9)</cell><cell>46 (41.7)</cell><cell>81 (65.3)</cell><cell>20 (45.5)</cell></row><row><cell>Race, n (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Black/African American</cell><cell>41 (15.5)</cell><cell>16 (18.0)</cell><cell>20 (16.1)</cell><cell>7 (15.9)</cell></row><row><cell>White</cell><cell>200 (75.8)</cell><cell>67 (75.3)</cell><cell>99 (79.8)</cell><cell>35 (79.5)</cell></row><row><cell>Other</cell><cell>23 (8.7)</cell><cell>6 (6.7)</cell><cell>5 (4.0)</cell><cell>2 (4.5)</cell></row><row><cell>TSS, mean (SD)</cell><cell>1.72 AE 0.76</cell><cell>1.77 AE 0.73</cell><cell>2.40 AE 0.35</cell><cell>2.36 AE 0.35</cell></row><row><cell>Range</cell><cell>0-3</cell><cell>0 -3</cell><cell></cell><cell></cell></row><row><cell cols="2">TSS, total symptom score; SD, standard deviation.</cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>MP-AzeFlu: novel intranasal formulation of azelastine hydrochloride and fluticasone propionate (FP) in a single spray.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.Allergy</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">MP-AzeFlu for paediatric allergic rhinitisBerger et al.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>We thank Dr Ruth Murray (Ireland) for assistance in editing this manuscript.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest</head><p><s>All authors are members of Meda's Dymista Paediatric Advisory Board.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Authors' contributions</head><p><s>All authors have contributed to acquisition of data and/or interpretation of data, drafting of the article and revising it critically for important intellectual content and have provided final approval for this version to be published.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Brozek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Baena-Cagnani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bonini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Canonica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Casale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="466" to="476" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Allergic rhinitis is associated with poor asthma control in children with asthma</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>De Groot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nijkamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Duiverman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Brand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thorax</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="582" to="587" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Allergic rhinitis as a predictor for wheezing onset in school-aged children</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Rochat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Illi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ege</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Keil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Wahn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="1170" to="1175" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study</title>
		<author>
			<persName><forename type="first">S</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Khan-Wasti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fletcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cullinan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sheikh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="381" to="387" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Allergic rhinitis in schoolaged children with asthma -still under-diagnosed and under-treated? A retrospective study in a children&apos;s hospital</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ruokonen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kaila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Haataja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Korppi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Paassilta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="e149" to="e154" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Meltzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ratner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bachert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Carr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Canonica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Arch Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="page" from="369" to="377" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis</title>
		<author>
			<persName><forename type="first">W</forename><surname>Carr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bernstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lieberman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Meltzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bachert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Price</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="1282" to="1289" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bhatia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bachert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Investig Allergol Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="495" to="503" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study</title>
		<author>
			<persName><forename type="first">L</forename><surname>Klimek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bachert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mosges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Munzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Virchow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy Asthma Proc</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="40" to="47" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lieberman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hadley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Munzel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol Pract</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="179" to="185" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Efficacy and safety of once-daily fluticasone furoate nasal spray in children with seasonal allergic rhinitis treated for 2 wk</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">O</forename><surname>Meltzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tripathy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ellsworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Philpot</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="279" to="286" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Efficacy and safety of beclomethasone dipropionate nasal aerosol in pediatric patients with seasonal allergic rhinitis</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Storms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Segall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Mansfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Amar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kelley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ding</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Allergy Asthma Immunol</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="408" to="414" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">An integrated analysis of the efficacy of fluticasone furoate nasal spray on individual nasal and ocular symptoms of seasonal allergic rhinitis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Maspero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Walters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Philpot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Naclerio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Fokkens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy Asthma Proc</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="483" to="492" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Parents and school children reported symptoms and treatment of allergic disease differently</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Danell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bergstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Wahlgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hallner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bohme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kull</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="783" to="789" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Factors associated with concordance between parental-reported use and dispensed asthma drugs in adolescents: findings from the BAMSE birth cohort</title>
		<author>
			<persName><forename type="first">E</forename><surname>Dahlen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Almqvist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bergstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wettermark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kull</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacoepidemiol Drug Saf</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="942" to="949" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title level="m" type="main">Randomized trial of the safety of MP29-02* compared with fluticasone propionate nasal spray in children aged =4 years to &lt;12 years with allergic rhinitis. Presented at the Paediatric Allergy &amp; Asthma Congress</title>
		<author>
			<persName><forename type="first">W</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ratner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Soteres</surname></persName>
		</author>
		<ptr target="http://www.eaaci-paam2015.com/PAAM2015-Abstracts/abstracts/PAAM_2015_PP76.pdf" />
		<imprint>
			<date type="published" when="2015-10">Oct 2015</date>
			<pubPlace>Berlin, Germany</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title level="m" type="main">MP-AzeFlu for nasal and ocular symptom relief in children with seasonal allergic rhinitis: importance of patient symptom assessment</title>
		<author>
			<persName><forename type="first">W</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">O</forename><surname>Meltzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Amar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Muraro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wickman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Just</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
		<respStmt>
			<orgName>Accepted by European Academy of Allergy and Clinical Immunology Congress</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">MP-AzeFlu and time to clinically-meaningful response in the treatment of children with seasonal allergic rhinitis: importance of patient symptom assessment</title>
		<author>
			<persName><forename type="first">W</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">O</forename><surname>Meltzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Amar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Muraro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wickman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Just</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Accepted by European Academy of Allergy and Clinical Immunology Congress</title>
				<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schunemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fonseca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Samolinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bachert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Canonica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="1372" to="1392" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
